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Abstract
RNA interference (RNAi)-based sequence-specific gene silencing is applied to identify gene function and also possesses
great potential for inhibiting virus replication both in animals and plants. Small interfering RNA (siRNA) molecules are the
inducers of gene silencing in the RNAi pathway but may also display immunostimulatory activities and promote apoptosis.
Canonical siRNAs are 21 nucleotides (nt) in length and are loaded to the RNA Induced Silencing Complex when introduced
into the cells, while longer siRNA molecules are first processed by endogenous Dicer and thus termed Dicer-substrate siRNA
(DsiRNA). We have applied RNA polymerases from bacteriophages T7 and phi6 to make high-quality double-stranded RNA
molecules that are specific for the UL29 gene of herpes simplex virus (HSV). The 653 nt long double-stranded RNA
molecules were converted to siRNA and DsiRNA pools using Dicer enzymes originating from human or Giardia intestinalis,
producing siRNAs of approximately 21 and 27 nt in length, respectively. Chemically synthesised 21 and 27 nt single-site
siRNA targeting the UL29 were used as references. The impact of these siRNAs on cell viability, inflammatory responses,
gene silencing, and anti-HSV activity were assayed in cells derived from human nervous system and skin. Both pools and the
canonical single-site siRNAs displayed substantial antiviral activity resulting in four orders of magnitude reduction in virus
titer. Notably, the pool of DsiRNAs caused lower immunostimulation than the pool of canonical siRNAs, whereas the
immunostimulation effect was in relation to the length with the single-site siRNAs. Our results also propose differences in
the processivity of the two Dicers.
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Introduction
RNA interference (RNAi) is an ancient mechanism of gene
silencing for diverse eukaryotes [1]. The key components of the
RNAi machinery are Dicer and Argonaute endonucleases. Dicer
initiates endogenous RNAi by cleaving long double-stranded RNA
(dsRNA) molecules into small fragments, referred to as small
interfering RNAs (siRNAs) [2]. The siRNAs enter into the RNA
Induced Silencing Complex (RISC) with subsequent association of
one of the two strands (guide strand) with Argonaute protein,
a core component of the RISC. This leads to Argonaute-mediated
sequence-specific cleavage of messenger RNA (mRNA) sequence
complementary to the bound guide strand [3].
The discovery that exogenous siRNA molecules can trigger the
RNAi pathway [4] provided a possibility to generate new
therapeutic approaches for the treatment of a wide spectrum of
diseases, including genetic disorders, cancer and viral infections
[5]. Currently, there are two techniques to generate siRNA
molecules for RNAi applications: chemical synthesis [6] and
enzymatic production from target-specific DNA templates using
RNA polymerases [7–10]. In the course of the enzymatic reaction
it is possible to synthesize both siRNA [8,11] and long dsRNA
molecules [7,9]. The latter can be subsequently cleaved in vitro by
Dicer enzyme generating a pool of target-specific siRNAs
representing sequences along the entire region of interest
[7,9,12,13]. Although chemical synthesis of single-site siRNAs is
the main approach in current RNAi applications, the pools may
better maintain their silencing potency in long term usage, in
particular when applied to combat viral infections, by reducing the
probability of functional escape mutants [14–16]. As the
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concentration of each siRNA species in the pool is low, the pools
may also be less potent in inducing off-target effects than the single
siRNAs [17].
Depending on the origin, Dicer produces siRNA molecules of
slightly different lengths. Human Dicer (HD) generates siRNAs of
approximately 21 to 23 nt [9,18,19]. These, or equal sized
chemically synthesized siRNA molecules, have been widely used
for a variety of applications and usually referred to as conventional
or canonical siRNA molecules. Dicer from the protozoan parasite
Giardia intestinalis (GD) cuts dsRNA molecules into longer
fragments producing siRNAs of 25 to 27 nt [12,20]. Although
numerous studies indicate that both size classes of siRNA
molecules can induce RNAi in mammalian cells [12,21–24] there
is still an ongoing debate on the possibility to utilize siRNA
molecules longer than canonical siRNAs for therapeutic purposes
[12,23–25].
It has been demonstrated [25] that chemically synthesized 27-nt
siRNA is a substrate for Dicer enzyme both in vitro and in vivo.
Later it was proved that enzymatically generated 27-nt siRNAs
can also be processed by recombinant HD [12]. Therefore, upon
introduction into mammalian cells 27-nt RNA duplexes can be
recognized and processed by endogenous Dicer potentially
advancing siRNA loading into the RISC complex [25]. Accord-
ingly, siRNAs of 27 nt in length, designated as Dicer-substrate
siRNAs (DsiRNAs), have been shown to be more efficient in
inducing RNAi than the canonical 21-nt siRNAs, especially at
subnanomolar concentrations [25]. However, other studies have
indicated equal silencing potency for both 21-nt and 27-nt siRNA
molecules [12,21–24]. Furthermore, it has been proposed that
longer siRNAs are more immunostimulatory than canonical
siRNAs in both cell cultures and animals [23,24]. Longer siRNAs
were also shown to induce a substantial decrease in viability of
some cell lines [24].
Herpes simplex virus type 1 (HSV-1) is a medically important
virus, causing a variety of significant infections, such as oral and
skin infections, an increasing proportion of genital herpes, ocular
infections, and the rare but severe HSV encephalitis. Single-site
siRNAs have been applied to suppress HSV-1 infections in
cultured cells using selected target-sequences from the HSV genes
encoding VP16 protein and the DNA polymerase [26], glycopro-
tein E [27], and infected cell protein (ICP) 4 [11,28]. Furthermore,
RNAi has yielded promising results in an animal model of genital
herpes (HSV-2) [29] where the single siRNAs used targeted HSV
genes UL29 (a DNA-binding protein, ICP8) and UL27 (glycopro-
tein B). Many genes of HSV-1 and -2 have significant homology,
and could serve as targets for RNAi.
In the present study we compared the enzymatic activities of
HD and GD, evaluated the cellular responses induced by
canonical siRNA and DsiRNA molecules and studied the potency
of HSV-specific siRNA molecules to block HSV-1 infection in
human skin- and nervous system-derived cell lines. For the current
study, we chose the prototypic HSV-1 strain 17+ as a target,
because its genomic sequence is known and it infects well both
types of host cells included in our study. The specific aims were to
analyze if enzymatically produced siRNA pools could be applied
to control HSV infections and to evaluate the possible siRNA
length-dependent variation in antiviral and innate immune
responses induced by pools of siRNA molecules. Therefore, we
created two pools of siRNA molecules, processed either by HD or
GD, targeting the UL29 gene of HSV-1. These were compared to
the 21- or 27-nt single-site UL29-specific siRNAs or control RNAs
representing non-specific sequences. The results suggest that
neither canonical nor DsiRNAs influenced cell viability despite
a slight up-regulation of interferon pathway genes. Both siRNA
pools demonstrated equal potency to suppress virus replication in
both cell types, while the 21- and 27-nt single-site siRNAs
displayed significantly different immunostimulatory and antiviral
activities, especially in the nervous system-derived cell line.
Methods
Cell Lines, Plasmids and Bacterial Strains
Transfection experiments were carried out in human glioma
U373MG (ATCC) and human epithelial HaCaT [30] cell lines
maintained in high glucose Dulbecco’s modified Eagle’s Medium
(hg-DMEM, Gibco) supplemented with 2 mM L-glutamine and
10% heat inactivated fetal calf serum (FCS, PromoCell) or in low
glucose DMEM (DMEM) supplemented with 7% FCS, re-
spectively. African green monkey (Vero; ATCC) cells were
maintained in DMEM supplemented with 2 or 7% FCS. All cells
were incubated at +37uC in 5% CO2, unless otherwise stated.
The selected target sequence for RNAi within the UL29 gene of
HSV-1 prototype strain 17+ (GenBank accession number
NC_001806.1) was amplified by PCR using primers containing
restriction sites for EcoRI and HindIII (Table S1). The amplified
fragment was cloned into the multiple cloning site of pET32b
(Novagen) to generate plasmid pET32UL29. Plasmid pCR3.1-
eGFP [7] was used to produce an siRNA pool against enhanced
green fluorescent protein gene (eGFP). Plasmid pLM659 [31]
contains the complementary DNA (cDNA) copy of bacteriophage
phi6 genome segment S and was used as a template for the
production of the 88 base pair (bp) long dsRNA (88-bp dsRNA).
Escherichia coli strain DH5a was used for propagation of
pET32UL29 and pCR3.1-eGFP. Plasmid pLM659 was main-
tained in E. coli JM109.
dsRNA and siRNA Molecules
The UL29- and eGFP-specific as well as the 88-bp phi6-specific
dsRNA molecules were generated using Replicator RNAi kit
(Thermo Scientific) according to the manufacturer’s instructions.
For the production of radioactively labeled dsRNA 5 mCi of
[a-32]UTP (3000 Ci/mmol; Perkin Elmer) was included in the
reaction, and unincorporated nucleotides were removed using
MicroSpin G-25 Columns (GE Healthcare) after the reaction.
DNA templates for dsRNA synthesis reactions were prepared by
PCR amplification of the target sequences from an appropriate
plasmid using primers containing T7 (TAATACGACTCACTA-
TAGGG) or phi6 (GGAAAAAAA) polymerase promoter se-
quences at their 59-ends (Table S1). Enzymatically synthesized
dsRNAs were separated from single-stranded RNAs by successive
precipitations with 2 M and 4 M LiCl [7]. The resulting dsRNA
pellets were washed thoroughly with 70% ethanol and dissolved in
RNAse-free Milli-Q water (Millipore).
The synthesized UL29- and eGFP-specific dsRNA molecules
were digested with either GD (PowerCut Dicer, Thermo
Scientific) or HD (BLOCK-iT Dicer enzyme, Invitrogen) for
16 h at 37uC according to the manufacturer’s instructions
applying 1 U Dicer/mg of dsRNA and dsRNA concentration of
0.2 mg/ml, unless otherwise stated. The reactions containing
radioactively labeled dsRNA were stopped at the indicated time
points by the addition of 26U loading buffer (10 mM EDTA
pH 8.0, 0.2% SDS, 0.05% bromphenol blue, 0.05% xylene
cyanol, 6% (v/v) glycerol, 8 M urea).
For cell culture experiments the desalted Dicer products (NAP
column, GE Healthcare) were loaded onto the anion-exchange
Gen-Pak FAX column (Waters), connected to the A¨KTApurifier
system (GE Healthcare), and eluted (0.5 ml/min) using a linear
NaCl gradient in 25 mM Tris-HCI buffer, pH 8.0. Fractions of
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0.5 ml were collected and those containing siRNA molecules were
combined, desalted with NAP columns, and concentrated using
a SpeedVac concentrator (Thermo Savant). Commercial single-
site UL29S siRNA (21-nt) [29] and UL29L DsiRNA (27-nt, Table
S1) were purchased from Dharmacon and the eGFPS and
GAPDH siRNAs were from Qiagen [13]. The single-site siRNAs
did not harbor any modifications.
RNA concentrations were determined by measuring the
absorbance at 260 nm using a NanoDrop 2000 spectrophotometer
(Thermo Scientific). For the evaluation of RNA integrity and
purity samples were routinely analyzed by electrophoresis in either
0.8% (dsRNA) or 2.5% (siRNA) agarose gel. The radioactively
labeled reaction products were analyzed in 6% polyacrylamide gel
in Tris-glycine buffer. After electrophoresis the signals were
collected by autoradiography on BAS1500 image plates (Fujifilm),
which were scanned using a Fuji BAS-1500 phosphorimager
(Fujifilm).
Transfection and Cell Viability
Enzymatically synthesized siRNA pools, commercial single-site
siRNAs, 88-bp dsRNA or water were transfected with Lipofecta-
mine RNAiMAX (Invitrogen) according to manufacturer’s for-
ward transfection protocol using 96-well plates. At the recom-
mended confluency the number of cells per well was
approximately 30 000 or 15 000 for HaCaT and U373MG cell
lines, respectively. The transfection efficiency was visually assessed
using 4 pmol of fluorescein-labeled siRNA (Label IT RNAi
Delivery Control, Mirus), and fluorescence was detected with
Zeiss AxioVert 200 M microscope. The transfection efficiency was
further monitored with 10 pmol of unlabeled human GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) -specific siRNA
(HS_GAPDH_3 FlexiTube siRNA, Qiagen) by measuring
changes in the mRNA levels of GAPDH gene using real-time
quantitative reverse transcription PCR (qRT-PCR; see below).
Cell viability was assessed 48 h post transfection with CellTiter-
Glo luminescent cell viability assay (Promega) [32].
Virus Propagation and Titration
Vero cells, grown in roller flasks at +35uC and maintained in
DMEM supplemented with 2% FCS, were infected with HSV-1
prototype strain 17+ at multiplicity of infection 0.01 and the
infection was allowed to spread to the entire culture. The cell
debris was removed from the infected culture by centrifugation at
21006gavg, +4uC for 10 minutes. Viruses were collected from the
resulting supernatant by centrifugation at 313006gavg, +4uC for
90 minutes. The virus-containing pellet was dissolved in MNT-
buffer [20 mM MES (Sigma), 100 mM NaCl, 30 mM Tris 7.4 pH
for 24 h in +4uC]. The virus stock was stored in aliquots at –70uC.
HSV-1 titers were determined on Vero cells maintained in
DMEM supplemented with 7% FCS and 20 mg/ml human
immunoglobulin G using 12-well plates. The plaque forming units
(pfu) were counted from infected cells fixed with methanol for
3 min and stained with 0.1% crystal violet in 2% ethanol three
days post infection.
RNA-transfected U373MG and HaCaT cells in 96-well plates
were infected with 1000 pfu/well of HSV-1 4 h post transfection.
Prior to infection cells were washed twice with RPMI 1640 (Gibco)
supplemented with 0.1% bovine serum albumin. Infection was
performed by addition of 100 ml of medium containing the virus.
After 1–1K h post infection cells were washed three times and
finally covered with 200 ml of culture medium per well. 48 h post
transfection cells were collected for RNA extraction and the
amount of released viruses in the culture medium was determined
by plaque titration.
Quantitative RT-PCR
Total cellular RNA was isolated from cells using TRI Reagent
(MRC) according to manufacturer’s instructions. DNase-treated
(Fermentas) cellular RNA was reverse transcribed into cDNA
using RevertAid H Minus Reverse Transcriptase (Fermentas) and
random hexamer primers (Fermentas). cDNA samples were then
amplified using Maxima SYBR Green/ROX qPCR Master Mix
(Fermentas). qRT-PCR was performed with Rotor-Gene Q real-
time instrument (Qiagen) as described earlier [33]. The sequences
for the gene specific primers are shown in the Table S1. Relative
copy number values of each studied mRNA were obtained by
standardization against GAPDH mRNA copy numbers in the
corresponding sample. In the GAPDH knockdown experiment
GAPDH mRNA levels were standardized against b-actin mRNA
levels.
Computational Analyses
Basic Local Alignment Search Tool BLAST [34] and
miRBASE [35] were applied in the validation of the siRNA
target sequence. Signal intensities of radioactively labeled dsRNA
bands were quantitated using 1D Evaluation module of Aida
Image Analyzer v. 4.5 software (Raytest Isotopenmebgera¨te
GmbH). Statistical analyses were performed using IBM SPSS
Statistics 20 software. Mann-Whitney U test was used to calculate
significance and threshold was set to p,0.05.
Results
Enzymatic Production of siRNA Molecules
Selection of the target-sequence within UL29 gene of HSV-
1. For the present work a 653 nt long target-sequence for RNAi
was selected from the UL29 gene coding for the essential ICP8
protein of HSV. The target sequence selection was based on
minimal homology with the host genome and maximal homology
within to date sequenced HSV strains of types 1 and 2 (GenBank
accession number NC_001806.1, GU734771.1, GU734772.1 and
NC_001798.1). The selected region (nucleotides 59301 to 59953
of UL29 gene from HSV-1 strain 17+) covers the target-site of the
previously used siRNA [29], which we here designate as UL29S (S
for small, 21-nt siRNA; Table S1). An extended version of this
single-site siRNA was also designed (UL29L; L for long, 27-nt
siRNA; Table S1). Non-specific control dsRNA and siRNA
molecules were derived from eGFP and Pseudomonas phage phi6
genome (88 bp long fragment from the S genome segment; [36]).
The UL29-, eGFP- and Pseudomonas phage phi6-specific
dsRNA molecules were generated from the corresponding DNA
(or cDNA) sequences by in vitro transcription using T7 DNA-
dependent RNA polymerase with subsequent replication of the
produced single-stranded RNA molecules by phi6 RNA-depen-
dent RNA polymerase [7]. The purified UL29- and eGFP-specific
dsRNA molecules were afterwards digested to provide siRNA
pools using either HD (to obtain 21- to 23-nt siRNAs) or GD (25-
to 27-nt siRNAs) enzymes (Figure 1A). The siRNA pools were
designated as UL29HD, UL29GD, and eGFPGD.
dsRNA processing and siRNA production by GD and
HD. The efficiency of dsRNA cleavage and siRNA production
by HD and GD was initially evaluated using internally labeled
UL29 dsRNA molecules as a substrate (Figure 1A and B). Aliquots
were sampled from HD- and GD-directed reactions at different
time points (from 30 s to 24 h) for subsequent electrophoretic
analysis (Figure 1A). siRNA-sized molecules were detected already
after 1 min and by 16 h (960 min; Figure 1) the reactions were
completed. Longer incubation time (up to 24 h) did not result in
further decrease in full length dsRNA amount (Figure 1B, upper
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panel) or increase in siRNA amount (Figure 1B, lower panel). Full-
length dsRNA processing by GD was faster than by HD (Fig. 1B,
upper panel). However, this did not influence the kinetics of
siRNA product accumulation (Fig. 1B, lower panel). The signal for
partially processed dsRNA molecules was evidently higher in GD-
than in HD-directed reactions (Figure 1A) suggesting that HD
possesses higher processivity on a single dsRNA substrate than
GD.
Figure 1. Generation of anti-UL29 siRNA pools using GD and HD. Internally labeled UL29 dsRNA was incubated with either HD or GD (1 U of
enzyme was used for each mg of dsRNA). (A) Samples taken from the HD- (left panel) and GD- (right panel) directed reactions at the indicated time
points were analyzed on 6% polyacrylamide gel. The mobility of substrate- and product-length dsRNA molecules is indicated on the left. (B) Kinetics
of dsRNA substrate processing by HD and GD (upper panel) and time-dependent accumulation of siRNA product in the course of Dicer reaction
(lower panel). The dsRNA cleavage (%) (B, upper panel) was calculated as a ratio of the signal intensities corresponding to the full-length dsRNA in
each sample and the undigested substrate dsRNA (time point zero). The relative siRNA amount (B, lower panel) is presented as a percentage of the
signal intensity of the whole sample. The error bars represent the standard deviation of the mean from two independent experiments. (C) Viability of
HaCaT (upper panel) and U373MG (lower panel) cells 48 h after transfection with 1 pmol, 5 pmol or 10 pmol of dsRNA molecules. 88-bp dsRNA was
applied only in 1 and 5 pmol amounts. UL29GD, GD-digested anti-UL29 siRNA pool; UL29HD, HD-digested anti-UL29 siRNA pool; UL29L, 27-nt
chemically synthesized anti-UL29 siRNA; UL29S, 21-nt chemically synthesized single anti-UL29 siRNA.
doi:10.1371/journal.pone.0051019.g001
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Enzymatically produced HPLC-purified siRNA pools do
not cause toxic drop in cell viability. The produced
UL29HD, UL29GD and eGFPGD siRNA pools (as well as the
88 bp long phi6-specific dsRNA fragments) were purified by
anion-exchange chromatography with subsequent size exclusion
chromatography to desalt RNA samples and remove RNA
molecules which are longer than 30 bp or shorter than approx-
imately 10 bp. It is crucially important that purified siRNA pools
do not contain traces of undigested or partially digested dsRNA
molecules that are longer than 30 bp as such molecules have
a strong potency to induce IFN pathways and cellular apoptosis
[37]. To verify the quality of the applied purification procedure we
transfected human nervous system (glioblastoma-astrocytoma)-
derived U373MG and human skin-derived HaCaT (keratinocyte)
cells on 96-well plates with 1, 5 or 10 pmol of siRNA pools
produced using either GD or HD (Figure 1C). Chemically
synthesized single-site siRNAs (UL29S and UL29L) were applied
as reference siRNAs. The transfectability of the cell lines was
verified with fluorescein-labeled siRNA (data not shown). For
quantitative measurements of the transfection efficiency, we
transfected a validated commercial GAPDH siRNA into both cell
lines and measured the GAPDH mRNA knockdown level by qRT-
PCR (Figure S1). Transfection of 10 pmol/well of the GAPDH
siRNA resulted in 98% decrease in GAPDH expression in
U373MG cells and in 65% decrease in HaCaT cells (p,0.01
for both cell lines in comparison to control transfections).
The viability of HaCaT cells did not differ between water- and
siRNA-transfected cells (Figure 1C). Likewise, transfection of
U373MG culture with 1 pmol of siRNAs did not significantly
decrease the number of viable cells. However, at higher siRNA
doses the viability of U373MG cells was slightly decreased (,20%
reduction). The 88-bp dsRNA caused a clear reduction in the
viability of HaCaT cells, and even more prominent effect was
observed in U373MG cultures (Figure 1C). This decrease is likely
related to the strong activation of interferon responses by the 88-
bp dsRNA [36] (see also Figure 2).
Induction of the Interferon Response by siRNA Molecules
Single-site DsiRNA display stronger immunostimulatory
activity than its canonical counterpart. To investigate the
ability of enzymatically generated and chemically synthesized
canonical and DsiRNAs to induce IFN family genes, we treated
the cells with either 1 or 10 pmols of different siRNA molecules
and analyzed samples from three time points (8, 24 and 48 h) post
transfection with qRT-PCR for type I (IFN-a and IFN-b) and type
III (IFN-l1) interferon genes, and interferon-stimulated gene 54
(ISG54) expression (Figure 2; data not shown). As a positive
inducer of interferon induction we used the 88-bp dsRNA, which
is a potent activator of IFN genes with kinetics compatible with the
time points of our experiments [36].
As expected, we observed strong activation of IFN-b, IFN-l1
and ISG54 genes in response to 88-bp dsRNA with highly
significant (p,0.01) difference compared to all other treatments in
both HaCaT and U373MG cell lines at almost all time points
(Figure 2). The only exception was the relatively low ISG54
expression observed in HaCaT cells at 24 and 48 h post
transfection, which was in accordance with the generally mild
ISG54 response in this cell line (Figure 2C). Additionally, we could
observe only minimal alterations in the IFN-a gene expression
levels in both HaCaT and U373MG cells in all conditions (data
not shown).
Canonical single-site siRNA UL29S did not cause IFN
responses, whereas the UL29L DsiRNA induced significant
dose-dependent activation of most of the measured IFN pathway
genes in both cell lines at several time points (Figure 2).
The pool of HD-generated canonical siRNAs displays
elevated immunostimulatory activity. Both GD- and HD-
generated siRNA pools activated IFN-b, IFN-l1 and ISG54
expression in a dose-dependent manner (Figure 2). However,
after 8 h post transfection the higher dose of HD-produced siRNA
pool induced significantly (p,0.01) higher response than the other
siRNAs in both cell lines as indicated by the expression level of all
the genes studied (Figure 2). The same trend was evident also at
the later time points (Figure 2A and C), and in the case of IFN-l1
expression the differences between canonical siRNA and DsiRNA
pools (UL29HD and UL29GD, respectively) were statistically
significant (Figure 2B) at almost all time points.
Antiviral Activity of siRNA Molecules
UL29-specific siRNAs induce substantial inhibition of
HSV-1 replication. To explore the potential differences in the
RNA-dependent gene silencing activity of the HD- and GD-
produced siRNA pools (UL29HD and UL29GD) as well as the 21-
nt and 27-nt single-site siRNA molecules (UL29S and UL29L), we
infected siRNA-treated U373MG and HaCaT cells with HSV-1
strain 17+ and determined the viral progeny production by plaque
titration (Figure 3A). In addition, we evaluated the effect of the
UL29-specific siRNA molecules on the expression of the viral
target gene by real-time qRT-PCR (Figure 3B). The data obtained
demonstrated that all the specific anti-UL29 siRNA molecules
significantly reduced viral shedding and the UL29 gene expression,
whereas the non-specific anti-eGFP siRNA molecules (eGFPGD
pool and single-site eGFP-specific siRNA, eGFPS; Table S1) did
not (Figure 3).
Anti-UL29 siRNAmolecules demonstrate cell type-specific
differences in their ability to inhibit HSV
replication. Without siRNA treatment HSV-1 replicated in
both cell lines with approximately equal efficiency (Figure 3A).
Distinct antiviral effects were observed with all the HSV-specific
siRNA molecules. However, the degree of siRNA-induced
antiviral effects depended on the cell line used. Treatment of
U373MG culture with either GD- or HD-generated UL29-specific
siRNA pool resulted in a four orders of magnitude reduction in the
efficiency of HSV-1 replication, whereas in the HaCaT cells the
viral titers were dropped to approximately one-tenth of that
observed in the untreated controls (Figure 3A). The lower
efficiency of HSV inhibition in HaCaT cells could reflect, at least
partially, the differences in transfection competence between the
two cell cultures (Figure S1). Furthermore, qRT-PCR experiments
revealed that, unlike in U373MG cells, in HaCaT cell culture the
anti-UL29 pool composed of canonical siRNA molecules
(UL29HD) caused slightly higher reduction in the UL29 mRNA
levels than the corresponding DsiRNA pool (UL29GD)
(Figure 3B). However, these differences in mRNA levels did not
result in significant differences in the efficiency of virus replication
(Figure 3A).
Antiviral effects of UL29-specific single-site DsiRNA
molecules were less pronounced than the effects of other
HSV-specific siRNAs. In the HaCaT cells the antiviral effects
of the siRNA pools were more evident than those of the single-site
siRNA molecules (Figure 3A); the HaCaT cells transfected with
single-site canonical or Dicer-substrate UL29-specific siRNA
molecules had 2- and 3-fold higher viral titers, respectively, than
the cells treated with pools of canonical siRNAs or DsiRNAs,
respectively.
In the U373MG cells canonical single-site anti-UL29 siRNA
molecule (UL29S) displayed similar activity as the UL29-specific
Canonical and Dicer-Substrate Anti-HSV-siRNA Pools
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Figure 2. Innate immunity responses to siRNA pools and single-site siRNA molecules. HaCaT and U373MG cells were transfected with
either 1 (light grey) or 10 (dark grey) pmol of the indicated siRNA molecules; 1 pmol of 88-bp dsRNA (black bar) or water (control, grey bar); or left
untreated (control, white bar). The expression levels of IFN-b (A), IFN-l1 (B) or ISG54 (C) were assessed by qRT-PCR 8 h, 24 h or 48 h post transfection.
Values were normalized to the GAPDH housekeeping gene and shown on a logarithmic scale. The mean values+S.D. of at least two independent
experiments, each with a minimum of three biological replicates, are shown. Data were compared by Mann-Whitney U-test. The statistical
significance is indicated as (6) p , 0.01 or (¤) p , 0.05 against the controls; (**) p , 0.01 or (*) p , 0.05 against a group of comparison; (#) p , 0.01
against all other transfections. UL29GD, GD-digested anti-UL29 siRNA pool; UL29HD, HD-digested anti-UL29 siRNA pool; UL29L, 27-nt chemically
synthesized anti-UL29 siRNA; UL29S, 21-nt chemically synthesized single anti-UL29 siRNA. No significant signal was detected for IFN-l1 mRNA in
U373MG cell culture (B, right panel) if no dsRNA was applied (non- and mock-transfected cells).
doi:10.1371/journal.pone.0051019.g002
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siRNA pools (UL29HD and UL29GD), whereas the antiviral
effects of the single-site DsiRNA (UL29L) were less pronounced.
Thus, in the U373MG cells treated with single-site DsiRNA
molecules, the virus titer decreased only by approximately one
order of magnitude instead of four orders of magnitude observed
for the other virus-specific siRNA molecules (Figure 3A). The same
pattern of siRNA activities was detected also for the expression
level of UL29 gene (Figure 3B).
Discussion
A variety of approaches have been developed for the selection
and production of siRNA molecules for RNAi applications. In this
study, we have evaluated antiviral and immunostimulatory
activities of canonical siRNA and DsiRNAs pools and compared
to those obtained by chemically synthesized siRNAs.
HD and GD processed the 653 bp UL29-specific dsRNA with
approximately equal efficiency, and both HD- and GD-directed
reactions were completed in 16 h (Figure 1A and B). This differs
from the earlier studies on HD and GD where shorter substrate
molecules were applied and almost 100% cleavage was observed
already within 2 h [20,38]. Comparison of the reaction products
produced by the two enzymes revealed differences in the way of
dsRNA processing. In GD-directed reaction the amount of full
length dsRNA decreased faster than in HD-directed reaction
(Figure 1B, upper panel), and dsRNA processing by GD resulted
in generation of a pool of intermediate size products, that were not
as prominent in HD-catalysed reaction (Figure 1A). Both
phenomena indicate that HD has higher processivity on a single
Figure 3. Inhibition of HSV-1 replication by UL29-specific siRNA molecules. HaCaT and U373MG cells on 96-well plates were transfected
with 10 pmol of indicated siRNA molecules or water. After 4 h the cells were infected with 1000 pfu of HSV-1 and incubated for 44 h. (A) Dilutions of
the HaCaT and U373MG supernatant, collected 48 h after transfection (44 h post infection) were assayed for released virus by plaque formation on
Vero cell culture. (B) The relative expression of the target HSV-1 gene UL29 was measured by qRT-PCR from samples of the infected cultures. Values
were normalized to the GAPDH housekeeping gene and shown on a logarithmic scale. The mean values+S.D. are shown for six replicates. Data were
compared by Mann-Whitney U-test. The statistical significance is indicated as (6) p , 0.01 and (¤) p,0.05 against the controls; (*) p , 0.05 against
a group of comparison; (#) p , 0.01 against all other siRNA transfections. NT, no transfection; mock, transfection with water; eGFPGD, anti-eGFP
siRNA pool; eGFPS, single-site anti-eGFP siRNA; UL29GD, GD-digested anti-UL29 siRNA pool; UL29HD, HD-digested anti-UL29 siRNA pool; UL29L, 27-nt
single-site anti-UL29 siRNA; UL29S, 21-nt single-site anti-UL29 siRNA.
doi:10.1371/journal.pone.0051019.g003
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dsRNA molecule than GD. GD lacks multiple domains that are
present in HD [20]. The lack of one of these domains could
promote spontaneous dissociation of GD from the dsRNA
substrate molecule between each cleavage step.
Previous studies have indicated that long chemically synthetized
siRNA molecules (DsiRNAs) are more potent inducers of in-
terferon pathway genes than the canonical siRNAs [23,24] and,
consequently, it has been proposed that short siRNAs are more
safe to use in RNAi applications. Accordingly, we observed
stronger induction of all studied interferon pathway genes as
a result of transfection with the single-site DsiRNA UL29L than
with the canonical siRNA molecule UL29S (27 and 21 nt in size,
respectively) (Figure 2). Surprisingly, the effect of the length of the
siRNA molecules was different when enzymatically produced
siRNA pools were applied. Consequently, it appears that within
the range of siRNAs shorter than 30 nt there are other factors
than the length of the molecule contributing to the siRNA-induced
activation of innate immunity system. The effects of these factors
may totally shield the potential effects that are dependent on the
size of the molecule. As proposed previously [39], one such factor
could be the sequence of the siRNA molecule. In a pool of siRNA
molecules the sequence-related effects are averaged due to the low
concentration of individual siRNAs, whereas in the single-site
siRNA molecules such factors may contribute significantly.
Therefore, the results of the effect of the size using the siRNA
pools are likely more reliable than those obtained with single-site
siRNAs (Figure 2).
The HSV UL29-specific siRNAs induced substantial inhibition
of viral replication (Figure 3A). The effect was especially
prominent when human glioma cells were used, in which four
orders of magnitude reduction in virus production was observed.
Consequently, RNAi-based approaches could be applied to inhibit
HSV infections not only in epithelial cells, as shown previously
[29], but also in cells derived from the nervous system, which are
the natural hosts for neurotropic viruses such as HSV. The pools
of siRNAs appeared especially powerful in viral knockdown
(Figure 3A). Inhibition by the canonical single-site UL29S siRNA
was also substantial in the glioma-derived cell culture, but the
effect of UL29L DsiRNA was modest when compared to all the
other UL29-specific siRNAs (Figure 3A). Upon the introduction
into the cells, DsiRNAs are digested with cellular Dicer enzyme
[12,25] which results in the generation of a set of 21-mer
molecules possessing different potency [40]. In the case of the
single-site siRNA UL29L, these heterogenic siRNAs demonstrated
significantly lower gene silencing activity (U373MG cell line,
Figure 3A) although the original 27 bp siRNA comprises the
highly efficient UL29S sequence (Table S1). At the same time,
a substantial induction of inflammatory responses was observed
(Figure 2). Interestingly, the siRNA-induced suppression of HSV
replication was equal in cells transfected with HD- or GD-
generated siRNA pools presenting canonical and DsiRNAs,
respectively. This is in accordance with previous results [12] and
implies that the processing of siRNA by endogenous Dicer [25]
does not markedly improve the siRNA-induced silencing. Based
on earlier studies it was proposed that processing of exogenously
applied siRNA by endogenous Dicer could promote siRNA
incorporation into the siRNA pathway [25]. However, modified
siRNAs that are not processed by Dicer are also incorporated into
the RISC [41], and although required in drosophila, Dicer seems
to be dispensable for RISC loading in mammals [42]. Apparently,
the previously observed differences in the efficiency of siRNA
silencing by the two size classes of chemically synthesized siRNAs
reflects sequence-dependent variances introduced by Dicer
processing [40], which can be difficult to control when using
single-site siRNAs.
In conclusion, both HD and GD were equally efficient in the
generation of siRNA pools (Figure 1), and siRNA pools produced
using HD or GD did not significantly differ in their potency to
suppress HSV infection (Figure 3A). Although the enzymatically
produced siRNAs, unlike chemically synthesized ones, contained
trace amount of siRNA having 59-triphosphate (one triphosphate
in every twelfth or fifteenth siRNA in UL29GD and UL29HD
pools, respectively) which are capable of stimulating type I IFN
responses [11], transfection of cell cultures derived from human
skin or nervous system by either pool resulted only in mild
activation of genes involved in interferon pathway, especially when
the GD-produced DsiRNA pool was applied (Figure 2). Conse-
quently, both Dicers can potentially be used to produce siRNA
molecules for therapeutic applications.
Selection of target sequences is a critical step in the production
of single-site siRNA molecules as siRNA with different sequences
may have substantially different RNAi activity [43,44]. Further-
more, the siRNA-induced off-target effects [45] and immunosti-
mulatory activities may differ depending on the selected sequence
[39]. Although a variety of siRNA design tools have been
developed, not all potentially risky motifs have been discovered
[46] bringing additional complexity and unpredictability to the
selection process. The difficult design procedure of single-site
siRNAs can, however, be largely overcome by using pools of
siRNAs, applicable as single-site siRNAs, for example in a topical
fashion [29]. The topical delivery of siRNAs may be feasible for
treatment of ocular infections caused by HSV-1. Disease models
exist for HSV keratitis, where the efficacy and delivery of siRNA
pools can be further tested. The siRNA pools may be well suited
for antiviral applications, as it is unlikely that functional viral
escape mutants or variant viral strains would emerge when the
target-sequence is long [14–16].
Supporting Information
Figure S1 GAPDH knockdown level in HaCaT (A) and
U373MG (B) cells. HaCaT and U373MG cells were transfected
on 96-well plate with 10 pmol/well of either GAPDH or eGFPS
siRNA. The expression level of GAPDH gene was assessed 48 h
post transfection by real-time qRT-PCR. Values were normalized
to human b-actin gene. The mean values+S.D. of two in-
dependent experiments performed in triplicates are presented.
Data were compared by Mann-Whitney U-test. (**) p,0.01. NT,
non-transfected control; mock, mock-transfected control; eGFP,
cells transfected with non-specific anti-eGFP siRNA; GAPDH,
cells transfected with anti-GAPDH siRNA.
(TIF)
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